{"filing":{"accession_number":"0001140361-26-037371","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"ef20082626_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm"},"events":[{"id":34443,"run_id":31687,"accession_number":"0001140361-26-037371","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgA nephropathy, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks. This material clinical milestone for the partnered investigational drug program (licensed to Roche) could support regulatory approval prospects and future sales milestone payments.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38165,"accession_number":"0001140361-26-037371","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgA nephropathy, demonstrating statistically significant proteinuria reduction versus placebo. This is a material clinical milestone for a partnered investigational drug program that could affect regulatory approval prospects and commercial potential, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-defined event type. The disclosure centers on a significant operational/clinical development milestone rather than financial performance or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:06:08.680780+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38166,"accession_number":"0001140361-26-037371","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgAN, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks. This is a material clinical milestone for a partnered investigational drug (licensed to Roche) that could support regulatory approval and future sales milestone payments to Ionis. While this is a clinical development milestone rather than a traditional operational event, it does not fit the earnings_release category (no financial results disclosed) and represents a significant operational/strategic advancement in the company's pipeline that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:06:08.680780+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38165,"accession_number":"0001140361-26-037371","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgA nephropathy, demonstrating statistically significant proteinuria reduction versus placebo. This is a material clinical milestone for a partnered investigational drug program that could affect regulatory approval prospects and commercial potential, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-defined event type. The disclosure centers on a significant operational/clinical development milestone rather than financial performance or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:06:08.680780+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-09-23"},{"id":38166,"accession_number":"0001140361-26-037371","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgAN, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks. This is a material clinical milestone for a partnered investigational drug (licensed to Roche) that could support regulatory approval and future sales milestone payments to Ionis. While this is a clinical development milestone rather than a traditional operational event, it does not fit the earnings_release category (no financial results disclosed) and represents a significant operational/strategic advancement in the company's pipeline that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:06:08.680780+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-09-23"}]}